Current Concepts in Therapy of Chronic Rhinosinusitis and Nasal Polyposis

Gosepath, Jan; Mann, Wolf J.

doi:10.1159/000086075

Cited by 46 publications

(30 citation statements)

References 172 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Further, some patients are nonresponders after treatment with corticosteroids for 3 months and receive a functional endoscopic sinus surgery. The recourse required by these patients implies that the level of TGF-β1 is not modulated by corticosteroid treatment, indicating that corticosteroids show no effect on TGF-β1 expression in CRS, as suggested by the results of computed tomography/endoscopy, histopathologic examination, and patients’ complaints [35,36,37]. …”

Section: Potential Therapeutic Applications In Crsmentioning

confidence: 99%

Regulation of Transforming Growth Factor-β1 Activation and Expression in the Tissue Remodeling Involved in Chronic Rhinosinusitis

Kou

Yao

et al. 2012

ORL

View full text Add to dashboard Cite

Transforming growth factor-β1 (TGF-β1) plays a key role in the tissue remodeling processes involved in chronic rhinosinusitis (CRS), with the biological functions of secreted TGF-β1 regulated by multiple proteins. Among these regulators, latency-associated peptide and latent TGF-β-binding protein inhibit TGF-β1 function, whereas different proteases and integrins activate it. Progress in understanding the factors responsible for the bioactivity and expression of TGF-β1 has revealed that the dysregulation of TGF-β1 activation and expression is closely associated with the chronic respiratory inflammatory diseases involved in CRS. This review of the regulation of TGF-β1 activation and expression provides insight into the mechanism responsible for the different CRS subtypes, which will help further the investigation of novel therapy targets for the treatment of CRS.

show abstract

Section: Potential Therapeutic Applications In Crsmentioning

confidence: 99%

Regulation of Transforming Growth Factor-β1 Activation and Expression in the Tissue Remodeling Involved in Chronic Rhinosinusitis

Kou

Yao

et al. 2012

ORL

View full text Add to dashboard Cite

show abstract

“…(6,7) Surgery, often in combination with topical and systemic medical treatment, has been the primary approach for treating CRS. (3,8) An effective topical therapy may allow treatment of upper respiratory diseases prior to or after surgery and can potentially prevent surgery.…”

Section: Introductionmentioning

confidence: 99%

Drug Delivery to Paranasal Sinuses Using Pulsating Aerosols

Möller

Schuschnig

Bartenstein

et al. 2014

Journal of Aerosol Medicine and Pulmonary Drug Delivery

View full text Add to dashboard Cite

Chronic rhinosinusitis (CRS) is the major disorder of the upper airways, affecting about 10-15% of the total population. Topical treatment regimens show only modest efficacy, because drug delivery to the posterior nose and paranasal sinuses is still a challenge. Therefore, there is a high rate of functional endoscopic sinus surgery in CRS patients. Most nasally administered aerosolized drugs, like nasal pump sprays, are efficiently filtered by the nasal valve and do not reach the posterior nasal cavity and the sinuses, which are poorly ventilated. However, as highlighted in this review, sinus ventilation and paranasal aerosol delivery can be achieved by using pulsating airflow, offering new topical treatment options for nasal disorders. Radioaerosol inhalation and imaging studies in nasal casts and in healthy volunteers have shown 4-6% of the nasally administered dose within the sinuses. In CRS patients, significant aerosol deposition in the sinus cavities was reported before sinus surgery. After surgery, deposition increased to the amount observed in healthy volunteers. In addition, compared with nasal pump sprays, retention kinetics of the radiolabel deposited in the nasal cavity was prolonged, both in healthy volunteers and in CRS patients. These efficiencies may be sufficient for topical aerosol therapies of sinus disorders and, due to the prolonged retention kinetics, may reduce application modes, but have to be proven in future clinical trials. Pulsating aerosols may offer additional new topical treatment options of nasal and sinus disorders before as well as after surgery.

show abstract

“…mainstay of treatment for the past decades (Gosepath and Mann, 2005). The long-term success rate of endoscopic sinus surgery is reported as high as 76%.…”

mentioning

confidence: 99%

Topical Membrane Therapy for Chronic Rhinosinusitis

Shikani¹

2011

Peculiar Aspects of Rhinosinusitis

View full text Add to dashboard Cite

Current Concepts in Therapy of Chronic Rhinosinusitis and Nasal Polyposis

Cited by 46 publications

References 172 publications

Regulation of Transforming Growth Factor-β1 Activation and Expression in the Tissue Remodeling Involved in Chronic Rhinosinusitis

Regulation of Transforming Growth Factor-β1 Activation and Expression in the Tissue Remodeling Involved in Chronic Rhinosinusitis

Drug Delivery to Paranasal Sinuses Using Pulsating Aerosols

Topical Membrane Therapy for Chronic Rhinosinusitis

Contact Info

Product

Resources

About